会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • METHODS FOR PREDICTING SENSITIVITY OF TUMORS TO ARGININE DEPRIVATION
    • 用于预测肿瘤对ARGININE DEPRIVATION的敏感性的方法
    • WO2002063048A2
    • 2002-08-15
    • PCT/US2002/002822
    • 2002-02-01
    • PHOENIX PHARMACOLOGICS, INC.CLARK, Mike, A.ENSOR, Charles, MarkHOLTSBERG, Frederick, Wayne
    • CLARK, Mike, A.ENSOR, Charles, MarkHOLTSBERG, Frederick, Wayne
    • C12Q1/68
    • C12Q1/6883C12Q2600/158
    • The present invention provides methods for determining which cancer patients are susceptible to arginine depletion therapy and methods for treating cancer. The present invention also provides methods for predicting the appropriateness of arginine deprivation therapy for a cancer patient. The methods generally comprise obtaining a tumor sample from the cancer patient and detecting the presence or absence of evidence of urea cycle enzyme expression in the tumor sample. The absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is a candidate for arginine deprivation therapy, and the presence of evidence of urea cycle enzyme expression in said tumor sample is indicative of a cancer patient who is not a candidate for arginine deprivation therapy. Prior to, simultaneous with, or after testing the tumor sample, the method further comprises the steps of obtaining a non-cancerous sample from the cancer patient and detecting the presence or absence of evidence of urea cycle enzyme expression in the non-cancerous sample, wherein the absence of evidence of urea cycle enzyme expression in the non-cancerous sample and absence of evidence of non-cancerous sample in the tumor sample is indicative of a cancer patient who is not a good candidate for arginine deprivation therapy, the presence of evidence of urea cycle enzyme expression in the non-cancerous sample and the absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is a candidate for arginine deprivation therapy, and the presence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is not a good candidate for arginine deprivation therapy.
    • 本发明提供了确定哪些癌症患者对精氨酸消耗治疗敏感的方法以及用于治疗癌症的方法。 本发明还提供了用于预测癌症患者精氨酸剥夺疗法适宜性的方法。 方法通常包括从癌症患者获得肿瘤样品并检测在肿瘤样品中是否存在尿素循环酶表达的证据。 在肿瘤样品中没有尿素循环酶表达的证据指示了作为精氨酸剥夺治疗候选者的癌症患者,并且在所述肿瘤样品中存在尿素循环酶表达的证据表明癌症患者是 不是精氨酸剥夺治疗的候选人。 在测试肿瘤样本之前,同时或之后,所述方法还包括从癌症患者获得非癌性样品并检测在非癌样品中是否存在尿素循环酶表达的证据的步骤, 其中在非癌样品中没有尿素循环酶表达的证据和在肿瘤样品中没有非癌样本的证据表明癌症患者不是精氨酸剥夺治疗的良好候选者,证据的存在 在非癌样品中的尿素循环酶表达和在肿瘤样品中没有尿素循环酶表达的证据表明作为精氨酸剥夺治疗的候选者的癌症患者以及存在尿素循环酶表达的证据 肿瘤样本中的癌症患者不是精神分裂症治疗的良好候选者。